OncLive TV

Rona Yaeger, MD, discusses the rationale for launching an expansion cohort study based on findings from the CodeBreaK 101 study.

Billy Truong discusses the rationale for investigating the functions of ERK2 substrate binding modalities in patients with myeloproliferative neoplasms.

Janaki Neela Sharma, MD, discusses data with triplet therapies in patients with hormone-sensitive prostate cancer.

Sarah Crafton, MD, discusses the potential future of antibody-drug conjugates in patients with ovarian cancer.

Maria Hafez, MD, discusses differences in biomarker expression prior to and following neoadjuvant chemotherapy treatment in HER2-positive breast cancer.

Emily Arner, PhD, discusses research on the role of SETD2 loss in metastatic clear cell renal cell carcinoma ccRCC.

John Mascarenhas, MD, discusses the use of selinexor with ruxolitinib in JAK inhibitor–naive myelofibrosis, highlighting the phase 2 XPORT-MF-044 trial

Benjamin Garmezy, MD, discusses the impact of frontline combination regimens on patient outcomes in patients with renal cell carcinoma.

Nicholas P. McAndrew, MD, MSCE, discusses the implications of the phase 2 PHERGain study of chemotherapy de-escalation in patients with HER2-positive early breast cancer.

Jorge J. Castillo, MD, discusses the efficacy of treatment with iopofosine I 131 in patients with Waldenström macroglobulinemia.

Hamza Hashmi, MD, discusses a real-world study of the efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma.

Robert DeBernardo, MD, discusses the current role of PARP inhibitors in the frontline treatment landscape in ovarian cancer.

Minoo Battiwalla, MD, discusses findings from a study of outpatient care after CAR T-cell therapy in patients with hematologic malignancies.

Christos Kyriakopoulos, MD, discusses data from a phase 1/2 study of masofaniten plus enzalutamide in metastatic castration-resistant prostate cancer.

Julie M. Vose, MD, MBA, discusses the mitigation of toxicities with epcoritamab in an optimization cohort of patients with relapsed/refractory DLBCL.

Alexey Danilov, MD, PhD, discusses the use of minimal residual disease to predict outcomes in patients with follicular lymphoma.

David Samuel Dicapua Siegel, MD, discusses the potential use of carfilzomib, iberdomide, and dexamethasone in newly diagnosed multiple myeloma.

William G. Wierda, MD, PhD, discusses the genomic evolution of pirtobrutinib in pretreated chronic lymphocytic leukemia.

Teresa Caprice, PA-C, discusses the use of post-transplant cyclophosphamide to address disparities in transplant outcomes in racial and ethnic populations.

Sebastian Stintzing, MD, discusses treatment with fruquintinib plus best supportive care in the Q-TWIST analysis in metastatic colorectal cancer.

Ritu Salani, MD, discusses the de-escalation of therapy and unmet needs within the landscape of gynecologic oncology.

Ilyas Sahin, MD, discusses an assessment of the Northstar Response in patients with advanced gastrointestinal cancer undergoing active treatment.

Arnab Basu, MD, MPH, FACP, discusses the phase 2 MRD Gate RCC trial of molecular residual disease–guided adjuvant therapy in in renal cell carcinoma.

Jun Gong, MD, discusses efforts to address unmet needs in metastatic hormone-sensitive prostate cancer.

Saby George, MD, FACP, discusses the efficacy and safety of subcutaneous nivolumab in patients with clear cell renal cell carcinoma, according to findings from the phase 3 CheckMate 67T study.

Andrea B. Apolo, MD, discusses the AMBASSADOR Alliance A031501 trial of adjuvant pembrolizumab in locally advanced/muscle-invasive urothelial carcinoma.

Amanda Nizam, MD, discusses findings from the UNITE study of enfortumab vedotin after maintenance avelumab in patients with advanced urothelial carcinoma.

Dalia Kaakour, MD, discusses real-world findings on genomic testing patterns in patients with prostate cancer.

Nikita Sinha, MD, discusses the potential effects of onvansertib on endometroid endometrial cancer pathogenesis in a preclinical model.

Gabriella Smith, MD, discusses the predictive value of CA-125 KELIM score for outcomes with HIPEC during surgery in patients with epithelial ovarian cancer.